Abstract:Background: An outbreak of synthetic cannabinoid (SC)-associated coagulopathy and bleeding in Illinois, USA was determined to be due to inhalation of SC contaminated with brodifacoum (BDF), difenacoum (DiF), and bromadiolone (BDL), highly potent long-acting anticoagulant rodenticides (LAARs). Treatment with high-dose vitamin K1 (VK1) prevented mortality; however, plasma LAAR levels were not measured risking recurrence of coagulopathy and bleeding due to premature discontinuation. The goal of this study was to determine if plasma LAAR levels were reduced following standard of care treatment to normalize coagulopathy.Methods: Blood samples were collected from a cohort of 32 patients, and ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) analysis used to quantify plasma LAAR levels including enantiomers.Results: BDF was detected in 31 samples; 30 also contained DiF and 18 contained BDL. Initial plasma levels were 581 ± 87, 11.0 ± 1.9, and 14.9 ± 5.9 ng/mL for BDF, DiF, and BDL, respectively (mean ± SE). At discharge plasma, BDF levels remained elevated at 453 ± 68 ng/mL. Plasma half-lives for BDF, DiF, and BDL were 7.5 ± 1.3, 7.2 ± 1.9, and 1.8 ± 0.3 days, respectively. The half-life for trans-BDF enantiomers (5.7 ± 0.8 days) was shorter than for cis-enantiomers (7.6 ± 1.9 days). BDF half-lives were shorter, and coagulopathy normalized faster in patients receiving intravenous VK1 as compared to oral VK1. Patients prescribed VK1 at discharge had fewer re-admittances.Conclusions: These results demonstrate that plasma LAAR levels at discharge were elevated in poisoned patients despite normal coagulation, and that the route of VK1 administration affected LAAR pharmacokinetics and INR normalization. We propose plasma LAAR levels and coagulation be monitored concomitantly during follow-up of patients with LAAR poisoning. In patients treated with high-dose vitamin K1 for LAAR poisoning, plasma levels remained 40-fold above safe levels upon discharge from hospital.LAAR half-lives, normalization of coagulopathy, and readmittances were reduced by treatment with intravenous vitamin K1.

Bromadiolone may cause severe acute kidney injury through severe disorder of coagulation: a case report

An attempted homicidal poisoning with bromadialone

Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis: Two case reports.

Toxicity and Bioaccumulation of Bromadiolone to Earthworm Eisenia Fetida.

Iopromide-induced acute renal failure

Convulsive status epilepticus as the initial presentation of superwarfarin poisoning: a case report

Rodenticide poisoning leading to cerebral hemorrhage: A case report

Sympathomimetic syndrome, choreoathetosis, and acute kidney injury following "bath salts" injection

Severe and Recurrent Acute Kidney Injury Following Dichlorvos Exposure - A Case Report

Acute renal failure induced by diclofenac potassium

Thinking Induced by Acute Kidney Injury of Diquat Poisoning: Cases Report

Acute renal failure induced by andrographolide injection:two case reports

[Acute kidney injury caused by acute dimethyl oxalate poisoning: a case report]

Bilateral adrenal hemorrhage caused by anticoagulant therapy after joint replacement surgery: One case report and literature review

Simultaneous subacute interstitial nephritis and anticoagulant-related nephropathy related to novel oral anticoagulants use

Rhabdomyolysis in Primary Aldosteronism: A Case Report and Review of the Literature

Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids

Chronic cardiac structural damage, diastolic and systolic dysfunction following acute myocardial injury due to bromine exposure in rats

Toxicology of chemical biocides: Anticoagulant rodenticides - Beyond hemostasis disturbance

Bromoacetic acid causes oxidative stress and uric acid metabolism dysfunction via disturbing mitochondrial function and Nrf2 pathway in chicken kidney

Inadvertent Intoxication with Salbutamol, Treated with Hemodialysis: A Case Report and Brief Review of the Literature